for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Flexion Therapeutics Inc

FLXN.OQ

Latest Trade

8.12USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

7.52

 - 

14.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.12
Open
--
Volume
--
3M AVG Volume
16.53
Today's High
--
Today's Low
--
52 Week High
14.35
52 Week Low
7.52
Shares Out (MIL)
49.92
Market Cap (MIL)
405.38
Forward P/E
-4.56
Dividend (Yield %)
--

Next Event

Flexion Therapeutics Inc Annual Shareholders Meeting

Latest Developments

More

Flexion Therapeutics Says Chief Medical Officer Scott Kelley Informed Of His Intention To Resign

Flexion Therapeutics Reports Fourth-Quarter And Full-Year 2020 Financial Results

Flexion Announces FDA Clearance Of Investigational NDA For FX301

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Flexion Therapeutics Inc

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Industry

Biotechnology & Drugs

Contact Info

10 Mall Rd Ste 301

BURLINGTON, MA

01803-4121

United States

+1.781.3057777

https://flexiontherapeutics.com/

Executive Leadership

Patrick J. Mahaffy

Independent Chairman of the Board

Michael D. Clayman

President, Chief Executive Officer, Director

David A. Arkowitz

Chief Financial Officer

Mark Levine

General Counsel and Corporate Secretary

Scott D. Kelley

Chief Medical Officer

Key Stats

1.77 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-4.490

2019

-3.930

2020

-2.530

2021(E)

-1.742
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.74
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-60.16
Return on Equity (TTM)
-48.44

Latest News

Latest News

BRIEF-Flexion Therapeutics Announces Pricing Of Public Offering Of Common Stock

* FLEXION THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Flexion Therapeutics Announces Proposed Public Offering Of Common Stock

* FLEXION THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Flexion Enters Into Amendment To Credit And Security Agreement

* FLEXION THERAPEUTICS INC - ON MAY 18, ENTERED INTO AN AMENDMENT TO OUR CREDIT AND SECURITY AGREEMENT

BRIEF-Flexion Therapeutics Says Intends To Initiate Human Trials Of FX301 In 2021

* FLEXION THERAPEUTICS - ANNOUNCES POSITIVE PRECLINICAL DATA SUPPORTING DEVELOPMENT OF FX301 FOR POST-OPERATIVE PAIN

BRIEF-Flexion Therapeutics Announces Zilretta License Agreement And Provides Business Update Amid Coronavirus Pandemic

* FLEXION THERAPEUTICS ANNOUNCES ZILRETTA® LICENSE AGREEMENT AND PROVIDES BUSINESS UPDATE AMID CORONAVIRUS PANDEMIC

BRIEF-Flexion Therapeutics Reports Fourth-Quarter Results

* FLEXION THERAPEUTICS REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

BRIEF-Flexion Therapeutics Q1 Loss Per Share $1.10

* FLEXION THERAPEUTICS REPORTS FIRST-QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

BRIEF-Flexion Therapeutics Names David Arkowitz As Chief Financial Officer

* FLEXION THERAPEUTICS NAMES DAVID ARKOWITZ AS CHIEF FINANCIAL OFFICER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up